Շվեյցարիա - գերմաներեն - Swissmedic (Swiss Agency for Therapeutic Products)

abbvie ag - risankizumabum - lnjektionslösung in einer fertigspritze - risankizumabum 150 mg, natrii acetas trihydricus corresp. natrium 0.209 mg, acidum aceticum glaciale, trehalosum dihydricum, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 1 ml. - plaque-psoriasis bei erwachsenen, psoriasis-arthritis - biotechnologika

Շվեյցարիա - գերմաներեն - Swissmedic (Swiss Agency for Therapeutic Products)

janssen-cilag ag - guselkumabum - injektionslösung in einer fertigspritze - guselkumabum 100 mg, saccharum, histidinum, histidini hydrochloridum monohydricum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 1 ml. - plaque psoriasis, psoriasis-arthritis - biotechnologika

Շվեյցարիա - գերմաներեն - Swissmedic (Swiss Agency for Therapeutic Products)

janssen-cilag ag - guselkumabum - injektionslösung im fertigpen - guselkumabum 100 mg, saccharum, histidinum, histidini hydrochloridum monohydricum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 1 ml. - plaque psoriasis, psoriasis-arthritis - biotechnologika

Շվեյցարիա - գերմաներեն - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - tofacitinibum - filmtabletten - tofacitinibum 5 mg zu tofacitinibi citras, excipiens pro compresso dunst. - selektives immunsuppressivum - synthetika

Շվեյցարիա - գերմաներեն - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - tofacitinibum - filmtabletten - tofacitinibum 10 mg zu tofacitinibi citras, color.: e 132, e 133, excipiens pro compresso dunst. - selektives immunsuppressivum - synthetika

Շվեյցարիա - գերմաներեն - Swissmedic (Swiss Agency for Therapeutic Products)

ucb-pharma sa - bimekizumabum - solution injectable en seringue préremplie - bimekizumabum 160 mg, glycinum, natrii acetas trihydricus, acidum aceticum glaciale, polysorbatum 80, aqua ad iniectabile, ad solutionem pro 1.0 ml corresp., natrium 0.45 mg. - psoriasis en plaques chez l'adulte - biotechnologika

Շվեյցարիա - գերմաներեն - Swissmedic (Swiss Agency for Therapeutic Products)

ucb-pharma sa - bimekizumabum - injektionslösung in einem fertigpen - bimekizumabum 160 mg, glycinum, natrii acetas trihydricus, acidum aceticum glaciale, polysorbatum 80, aqua ad iniectabile, ad solutionem pro 1.0 ml corresp., natrium 0.45 mg. - psoriasis en plaques chez l'adulte - biotechnologika

Եվրոպական Միություն - գերմաներեն - EMA (European Medicines Agency)

pfizer europe ma eeig - tofacitinib - arthritis, rheumatoide - immunsuppressiva - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 und 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.

Շվեյցարիա - գերմաներեն - Swissmedic (Swiss Agency for Therapeutic Products)

abbvie ag - risankizumabum - injektionslösung im fertigpen - risankizumabum 150 mg, natrii acetas trihydricus corresp. natrium 0.209 mg, acidum aceticum glaciale, trehalosum dihydricum, polysorbatum 20, aqua ad iniectabile ad solutionem pro 1 ml. - plaque-psoriasis bei erwachsenen; psoriasis-arthritis - biotechnologika

Շվեյցարիա - գերմաներեն - Swissmedic (Swiss Agency for Therapeutic Products)

iqone healthcare switzerland sa - imlifidasum - pulver für ein konzentrat zur herstellung einer infusionslösung - imlifidasum 11 mg, mannitolum, polysorbatum 80, trometamolum, dinatrii edetas, acidum hydrochloridum, pro vitro corresp. natrium 0.004 mg. - prévention du rejet de greffe suite à la transplantation d’organes solides - biotechnologika